Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug help seniors heal faster after a broken hip?

NCT ID NCT07179042

Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study tests whether metformin, a common diabetes drug, can help older adults recover muscle and function after a hip fracture. Sixty people aged 60 and older will take either metformin or a placebo daily for 4 months after surgery. The main goal is to see if the study is feasible and if metformin helps preserve thigh muscle size and improve mobility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin
What this could lead to
If it works, this could point toward a simple, low-cost way to improve recovery and prevent muscle loss after hip fracture in older adults.
What could go wrong
This is a very early pilot study with only 60 people, so results may not be conclusive. Metformin is generally safe but can cause stomach upset, and the study excludes people with kidney problems or diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 60y and older. * Displaced hip fracture (femoral neck, intertrochanteric femur, subtrochanteric femur fracture). * Low energy mechanism of injury (ground level fall, etc). * Operative treatment within 72 hours of injury. * Previously ambulatory. Exclusion Criteria: * History of kidney disease or failure (CKD \> stage 4; eGFR \< 45 mL/min/1.73m2). * History of diabetes mellitus (HbA1c \> 6.5). * Associated lower extremity fracture (ipsilateral or contralateral). * Pathologic fracture. * Presence of infection at the fracture site. * History of metabolic bone disease (Pagets, etc.). * Severe cognitive impairment (Six Item Screener with 3 or more errors). * Stage 5 Parkinson's Disease. * Open fracture. * Risk of developing metformin-associated hypoglycemia (e.g., hepatic impairment (by history or screening laboratory assessment), presence of hypoglycemia at screening, history of adrenal or pituitary insufficiency, alcohol use disorder, subjects unable to maintain normal oral intake). * Severe hepatic impairment (Child-Pugh C). * Expected survival \< 6 months (based on clinical judgement).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intertrochanteric femur fracture are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hip fracture muscular atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intertrochanteric femur fracture Muscle atrophy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Utah Orthopedics

    Salt Lake City, Utah, 84108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.